Galectin Therapeutics (GALT) Consolidated Net Income (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Consolidated Net Income of -$6.0 million in Q1 2026, down 14.21% quarter-over-quarter from -$5.3 million in Q4 2025, and up 37.24% on a YoY basis from -$4.4 million in Q1 2025.
Galectin Therapeutics (GALT) Consolidated Net Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$6.0 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 37.24% year-over-year to -$6.0 million; the TTM figure through Mar 2026 stood at -$23.7 million (up 49.14% YoY), while the FY2025 annual figure was -$27.3 million, up 42.71% from the prior year.
- Consolidated Net Income was -$6.0 million for Q1 2026 at Galectin Therapeutics, down from -$5.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$5.3 million in Q4 2025 to a low of -$14.1 million in Q4 2024.
- Historically, Consolidated Net Income has averaged -$9.5 million across 5 years, with a median of -$9.9 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income plunged 60.32% in 2022, then jumped 62.48% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at -$10.9 million in 2022, then gained by 5.29% to -$10.3 million in 2023, then slumped by 36.14% to -$14.1 million in 2024, then surged by 62.48% to -$5.3 million in 2025, then dropped by 14.21% to -$6.0 million in 2026.
- The last three Consolidated Net Income figures came in at -$6.0 million (Q1 2026), -$5.3 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | -6.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.03 Mn |
| Dec 31, 2025 | -5.28 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -6.43 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -14.07 Mn |
| Sep 30, 2024 | -10.47 Mn |
| Jun 30, 2024 | -12.48 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -10.33 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -10.76 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -9.89 Mn |
| Mar 31, 2022 | -10.16 Mn |
| Dec 31, 2021 | -7.70 Mn |
| Sep 30, 2021 | -8.25 Mn |
| Jun 30, 2021 | -8.28 Mn |